Irregular Periods: Labs to Order and Next Steps

What Counts as an Irregular Period

A normal menstrual cycle lasts 24 to 38 days, according to the International Federation of Gynecology and Obstetrics (FIGO) 2018 classification system [1]. Cycles that fall outside this window, vary by more than 7 to 9 days from cycle to cycle, or disappear for 90 days or longer meet the clinical definition of menstrual irregularity.

The terminology matters because it guides the workup. Oligomenorrhea refers to cycles longer than 35 days. Polymenorrhea describes cycles shorter than 21 days. Amenorrhea means no period for three consecutive months (or six months in someone with previously irregular cycles). Each pattern points toward a different set of causes. A woman bleeding every 45 days likely has a different problem than one bleeding every 18 days, and the lab approach reflects that distinction.

FIGO's PALM-COEIN classification separates structural causes (polyps, adenomyosis, leiomyoma, malignancy) from non-structural ones (coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, not yet classified) [1]. Your clinician uses this framework to decide whether the next step is bloodwork, imaging, or both.

Population data from the Women's Health Across the Nation (SWAN) study found that menstrual irregularity affects roughly 14% to 25% of women in their reproductive years, with the highest prevalence during the menopausal transition [2].

Why Periods Become Irregular

Ovulation drives the menstrual cycle. When the hypothalamic-pituitary-ovarian (HPO) axis misfires at any point, the result is an anovulatory or irregularly ovulatory cycle. The five most common culprits are PCOS, thyroid dysfunction, hyperprolactinemia, hypothalamic amenorrhea, and perimenopause.

PCOS accounts for up to 80% of anovulatory infertility cases [3]. It is the single most frequent endocrine disorder in reproductive-age women, affecting 8% to 13% of this population depending on diagnostic criteria used [3]. Excess androgens disrupt follicular development, stalling ovulation and producing long, unpredictable cycles.

Thyroid disease is the second most common hormonal cause. Hypothyroidism raises thyrotropin-releasing hormone (TRH), which in turn stimulates prolactin secretion and suppresses gonadotropin pulsatility. A 2015 cross-sectional analysis in the journal Thyroid found that women with subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) had a 1.8-fold higher odds of menstrual irregularity compared to euthyroid controls [4].

Hyperprolactinemia suppresses GnRH pulsatility directly. Prolactin levels above 100 ng/mL suggest a macroprolactinoma; levels between 25 and 100 ng/mL may reflect a microprolactinoma, medication side effect, or stalk compression [5]. Common drug causes include antipsychotics (risperidone, haloperidol), metoclopramide, and certain SSRIs.

Hypothalamic amenorrhea results from energy deficit, excessive exercise, or psychological stress. It presents with low or low-normal FSH, low LH, and low estradiol. The American Society for Reproductive Medicine (ASRM) published a committee opinion stating: "Functional hypothalamic amenorrhea is a diagnosis of exclusion that requires ruling out organic pituitary, thyroid, and ovarian pathology before attributing menstrual loss to energy deficit or stress" [6].

Perimenopause typically begins in the mid-40s and lasts 4 to 8 years. The Study of Women's Health Across the Nation (SWAN) demonstrated that cycle variability increases measurably 2 to 3 years before the final menstrual period, with FSH levels rising progressively as the ovarian follicle pool declines [2].

The First-Line Lab Panel

Order these labs on cycle day 2 to 4 if any cycle is present, or at any time if the patient is amenorrheic. That early-follicular timing captures baseline gonadotropin and estradiol levels before a dominant follicle is selected.

Core panel:

• Beta-hCG (pregnancy test). Always first. Always.
• TSH. Screens for both hypo- and hyperthyroidism.
• Prolactin. Drawn fasting, ideally in the morning, since levels fluctuate with meals and stress.
• FSH and LH. The ratio and absolute values help differentiate PCOS (LH:FSH ratio often >2:1), premature ovarian insufficiency (FSH >25 IU/L on two draws four weeks apart), and hypothalamic amenorrhea (both low).
• Estradiol. Low values (<20 pg/mL) suggest hypoestrogenism from hypothalamic or ovarian failure. Normal-to-high values with absent periods suggest anovulation with intact estrogen production.

Add-on panel (based on clinical suspicion):

• Total testosterone and DHEA-S if PCOS or androgen excess is suspected.
• 17-hydroxyprogesterone if late-onset congenital adrenal hyperplasia (LOCAH) is a concern; a morning level >200 ng/dL warrants an ACTH stimulation test [7].
• Hemoglobin A1c and fasting insulin if metabolic syndrome accompanies PCOS.
• Anti-Müllerian hormone (AMH) if diminished ovarian reserve or premature ovarian insufficiency (POI) is possible.

The Endocrine Society's 2013 clinical practice guideline on PCOS states: "All women presenting with menstrual irregularity should have thyroid function and prolactin measured before proceeding to a PCOS-specific workup" [8]. This two-step logic prevents premature labeling and missed diagnoses.

How to Read Your Results

The numbers tell a story, but only in context. A single lab value rarely makes a diagnosis. The pattern across multiple analytes is what matters.

High TSH (above 4.5 mIU/L) with low free T4: primary hypothyroidism. Levothyroxine 1.6 mcg/kg/day is standard replacement. Cycles typically normalize within 2 to 3 months of reaching a euthyroid state [4].

High prolactin (above 25 ng/mL): repeat the test fasting. If confirmed, obtain a pituitary MRI. Cabergoline 0.25 mg twice weekly is first-line for prolactinomas, normalizing prolactin in 85% of patients with microprolactinomas [5].

Elevated LH with normal or low FSH, elevated testosterone, normal prolactin, normal TSH: classic PCOS pattern. The Rotterdam criteria require two of three features: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound [3].

Elevated FSH (above 25 IU/L) on two separate draws, low estradiol, low AMH: premature ovarian insufficiency. Affects 1% of women under 40 [9]. Karyotype analysis and FMR1 premutation testing are recommended by ACOG Practice Bulletin No. 698 [9].

Low FSH, low LH, low estradiol, no structural lesion on MRI: functional hypothalamic amenorrhea. Treatment is the underlying cause: nutritional rehabilitation, training modification, or stress management. Estrogen-progestin therapy protects bone density while the HPO axis recovers.

When to Get Imaging

Not every irregular cycle requires an ultrasound. But specific findings make imaging necessary.

Transvaginal ultrasound is the first imaging step when the clinician suspects PCOS (to assess ovarian morphology), a structural uterine lesion (polyp, fibroid, adenomyosis), or an endometrial thickness concern in a woman with prolonged anovulatory bleeding. The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS updated the ultrasound threshold to 20 or more follicles per ovary (using transducers with a frequency of 8 MHz or greater) or an ovarian volume of 10 mL or more [10].

Pituitary MRI is indicated when prolactin is persistently elevated above 50 ng/mL, when prolactin is modestly elevated but the patient has visual field deficits or headaches, or when gonadotropins are low without an obvious functional explanation.

Saline infusion sonohysterography (SIS) offers better sensitivity than standard transvaginal ultrasound for intracavitary lesions. A 2017 meta-analysis in Ultrasound in Obstetrics & Gynecology reported SIS sensitivity of 94% and specificity of 81% for endometrial polyps [11].

Treatment by Cause

Therapy targets the underlying diagnosis. There is no single pill for "irregular periods."

PCOS. For women not seeking pregnancy, combined oral contraceptives (COCs) are first-line to regulate cycles and suppress androgens. Ethinyl estradiol 20 to 35 mcg combined with a progestin that has anti-androgenic activity (drospirenone, cyproterone acetate) addresses both cycle control and hirsutism [8]. Metformin 1,500 to 2,000 mg daily improves ovulatory rates in PCOS by roughly 30% to 40% compared with placebo, according to a Cochrane review of 44 trials [12]. For women seeking pregnancy, letrozole 2.5 to 7.5 mg on cycle days 3 to 7 is first-line ovulation induction; the NICHD Reproductive Medicine Network trial (N=750) demonstrated a 27.5% live birth rate with letrozole versus 19.1% with clomiphene [13].

Thyroid dysfunction. Levothyroxine for hypothyroidism; methimazole or propylthiouracil for hyperthyroidism. Cycle restoration follows euthyroid status. No additional gynecologic intervention is needed unless irregularity persists after 3 months of normal TSH [4].

Hyperprolactinemia. Cabergoline is preferred over bromocriptine due to superior efficacy and tolerability. A study in the New England Journal of Medicine showed cabergoline normalized prolactin in 83% versus 59% with bromocriptine (P<0.001) [5].

Hypothalamic amenorrhea. Nutritional rehabilitation is the primary treatment. The ASRM advises restoring energy availability above 30 kcal/kg lean body mass per day [6]. Hormone replacement (estradiol patch 0.1 mg plus cyclic micronized progesterone 200 mg for 12 days per month) protects bone while the axis recovers. Bone density loss begins within 6 months of amenorrhea onset.

Perimenopause. Low-dose COCs (20 mcg ethinyl estradiol) or cyclic progestin (medroxyprogesterone acetate 10 mg for 10 to 12 days monthly) manage both cycle unpredictability and vasomotor symptoms in eligible women. The North American Menopause Society (NAMS) 2022 position statement recommends individualizing hormone therapy based on time since menopause, symptom severity, and cardiovascular risk [14].

Protecting the Endometrium

Unopposed estrogen exposure from chronic anovulation is the reason irregular periods matter beyond inconvenience. Without regular progesterone exposure from ovulation, the endometrial lining thickens without shedding, raising the risk of endometrial hyperplasia and, over time, endometrial cancer.

A retrospective cohort study published in Obstetrics & Gynecology found that women with PCOS had a 2.7-fold increased risk of endometrial cancer compared to age-matched controls [15]. The risk is not theoretical. Any woman with more than 3 months of amenorrhea and intact estrogen production should receive a progestin challenge or cyclic progestin therapy. Micronized progesterone 200 mg for 12 to 14 days induces a withdrawal bleed and resets the endometrium. If no withdrawal bleed occurs, the estrogen level is likely too low to have stimulated significant endometrial growth, and the concern shifts toward hypoestrogenism rather than hyperplasia.

Lifestyle Modifications That Move the Needle

Weight loss of 5% to 10% of body weight restores ovulatory cycles in roughly 50% of overweight women with PCOS, according to a 2019 systematic review in Human Reproduction Update [16]. This is not a suggestion to "just lose weight." It is a measurable physiologic threshold at which insulin resistance improves enough to allow follicular development.

Exercise of 150 minutes per week at moderate intensity (brisk walking, cycling, swimming) independently improves insulin sensitivity and menstrual regularity in PCOS, even without weight loss [10]. Sleep quality matters too. Women sleeping fewer than 6 hours per night have higher cortisol, higher insulin, and more anovulatory cycles, based on SWAN data [2].

Stress reduction is harder to prescribe but measurable in its effects. Cortisol directly suppresses GnRH pulsatility. Cognitive behavioral therapy (CBT) for stress-related hypothalamic amenorrhea restored menses in 87.5% of participants versus 25% in the observation group in a small but well-designed RCT published in Fertility and Sterility [17].

When to See a Specialist

Primary care clinicians manage most menstrual irregularity effectively. Referral to reproductive endocrinology or gynecology is appropriate when: the initial workup suggests POI and the patient is under 40, when imaging reveals a structural lesion requiring surgical evaluation, when infertility has persisted for 6 to 12 months despite ovulation induction, or when the clinical picture does not fit any standard diagnostic category after thorough evaluation.

ACOG recommends that adolescents who have not achieved menarche by age 15, or within 3 years of thelarche, be referred for evaluation of primary amenorrhea [9]. For secondary amenorrhea, any woman with 3 or more months of missed periods deserves a workup. Waiting longer serves no clinical purpose.